Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease

Jane C. Burns, Brookie M. Best, Asuncion Mejias, Lynn Mahony, David E Fixler, Hasan S. Jafri, Marian E. Melish, Mary Anne Jackson, Basim I. Asmar, David J. Lang, James D. Connor, Edmund V. Capparelli, Monica L. Keen, Khalid Mamun, Gregory F. Keenan, Octavio Ramilo

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Objective: To investigate the safety, tolerability, and pharmacokinetics of the anti-tumor necrosis factor-α monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). Study design: We conducted a multicenter, randomized, prospective trial of second IVIG infusion (2 g/kg) versus infliximab (5 mg/kg) in 24 children with acute KD and fever after initial treatment with IVIG. Primary outcome measures were the safety, tolerability, and pharmacokinetics of infliximab. Secondary outcome measures were duration of fever and changes in markers of inflammation. Results: Study drug infusions were associated with cessation of fever within 24 hours in 11 of 12 subjects treated with infliximab and in 8 of 12 subjects retreated with IVIG. No infusion reactions or serious adverse events were attributed to either study drug. No significant differences were observed between treatment groups in the change from baseline for laboratory variables, fever, or echocardiographic assessment of coronary arteries. Conclusions: Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.

Original languageEnglish (US)
JournalJournal of Pediatrics
Volume153
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

Mucocutaneous Lymph Node Syndrome
Intravenous Immunoglobulins
Fever
Intravenous Infusions
Therapeutics
Pharmacokinetics
Outcome Assessment (Health Care)
Safety
Acute Disease
Infliximab
Pharmaceutical Preparations
Coronary Vessels
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Inflammation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease. / Burns, Jane C.; Best, Brookie M.; Mejias, Asuncion; Mahony, Lynn; Fixler, David E; Jafri, Hasan S.; Melish, Marian E.; Jackson, Mary Anne; Asmar, Basim I.; Lang, David J.; Connor, James D.; Capparelli, Edmund V.; Keen, Monica L.; Mamun, Khalid; Keenan, Gregory F.; Ramilo, Octavio.

In: Journal of Pediatrics, Vol. 153, No. 6, 12.2008.

Research output: Contribution to journalArticle

Burns, JC, Best, BM, Mejias, A, Mahony, L, Fixler, DE, Jafri, HS, Melish, ME, Jackson, MA, Asmar, BI, Lang, DJ, Connor, JD, Capparelli, EV, Keen, ML, Mamun, K, Keenan, GF & Ramilo, O 2008, 'Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease', Journal of Pediatrics, vol. 153, no. 6. https://doi.org/10.1016/j.jpeds.2008.06.011
Burns, Jane C. ; Best, Brookie M. ; Mejias, Asuncion ; Mahony, Lynn ; Fixler, David E ; Jafri, Hasan S. ; Melish, Marian E. ; Jackson, Mary Anne ; Asmar, Basim I. ; Lang, David J. ; Connor, James D. ; Capparelli, Edmund V. ; Keen, Monica L. ; Mamun, Khalid ; Keenan, Gregory F. ; Ramilo, Octavio. / Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease. In: Journal of Pediatrics. 2008 ; Vol. 153, No. 6.
@article{6999face007d46d5aff6643c57eedcb6,
title = "Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease",
abstract = "Objective: To investigate the safety, tolerability, and pharmacokinetics of the anti-tumor necrosis factor-α monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). Study design: We conducted a multicenter, randomized, prospective trial of second IVIG infusion (2 g/kg) versus infliximab (5 mg/kg) in 24 children with acute KD and fever after initial treatment with IVIG. Primary outcome measures were the safety, tolerability, and pharmacokinetics of infliximab. Secondary outcome measures were duration of fever and changes in markers of inflammation. Results: Study drug infusions were associated with cessation of fever within 24 hours in 11 of 12 subjects treated with infliximab and in 8 of 12 subjects retreated with IVIG. No infusion reactions or serious adverse events were attributed to either study drug. No significant differences were observed between treatment groups in the change from baseline for laboratory variables, fever, or echocardiographic assessment of coronary arteries. Conclusions: Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.",
author = "Burns, {Jane C.} and Best, {Brookie M.} and Asuncion Mejias and Lynn Mahony and Fixler, {David E} and Jafri, {Hasan S.} and Melish, {Marian E.} and Jackson, {Mary Anne} and Asmar, {Basim I.} and Lang, {David J.} and Connor, {James D.} and Capparelli, {Edmund V.} and Keen, {Monica L.} and Khalid Mamun and Keenan, {Gregory F.} and Octavio Ramilo",
year = "2008",
month = "12",
doi = "10.1016/j.jpeds.2008.06.011",
language = "English (US)",
volume = "153",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease

AU - Burns, Jane C.

AU - Best, Brookie M.

AU - Mejias, Asuncion

AU - Mahony, Lynn

AU - Fixler, David E

AU - Jafri, Hasan S.

AU - Melish, Marian E.

AU - Jackson, Mary Anne

AU - Asmar, Basim I.

AU - Lang, David J.

AU - Connor, James D.

AU - Capparelli, Edmund V.

AU - Keen, Monica L.

AU - Mamun, Khalid

AU - Keenan, Gregory F.

AU - Ramilo, Octavio

PY - 2008/12

Y1 - 2008/12

N2 - Objective: To investigate the safety, tolerability, and pharmacokinetics of the anti-tumor necrosis factor-α monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). Study design: We conducted a multicenter, randomized, prospective trial of second IVIG infusion (2 g/kg) versus infliximab (5 mg/kg) in 24 children with acute KD and fever after initial treatment with IVIG. Primary outcome measures were the safety, tolerability, and pharmacokinetics of infliximab. Secondary outcome measures were duration of fever and changes in markers of inflammation. Results: Study drug infusions were associated with cessation of fever within 24 hours in 11 of 12 subjects treated with infliximab and in 8 of 12 subjects retreated with IVIG. No infusion reactions or serious adverse events were attributed to either study drug. No significant differences were observed between treatment groups in the change from baseline for laboratory variables, fever, or echocardiographic assessment of coronary arteries. Conclusions: Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.

AB - Objective: To investigate the safety, tolerability, and pharmacokinetics of the anti-tumor necrosis factor-α monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). Study design: We conducted a multicenter, randomized, prospective trial of second IVIG infusion (2 g/kg) versus infliximab (5 mg/kg) in 24 children with acute KD and fever after initial treatment with IVIG. Primary outcome measures were the safety, tolerability, and pharmacokinetics of infliximab. Secondary outcome measures were duration of fever and changes in markers of inflammation. Results: Study drug infusions were associated with cessation of fever within 24 hours in 11 of 12 subjects treated with infliximab and in 8 of 12 subjects retreated with IVIG. No infusion reactions or serious adverse events were attributed to either study drug. No significant differences were observed between treatment groups in the change from baseline for laboratory variables, fever, or echocardiographic assessment of coronary arteries. Conclusions: Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=56049109048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049109048&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2008.06.011

DO - 10.1016/j.jpeds.2008.06.011

M3 - Article

VL - 153

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 6

ER -